Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry

Clinica Chimica Acta

Volumn 413, Issue 9-10, 2012, Pages 861-868

  Zhang, Tao ^a   Wu, Xiaoyan ^a   Yin, Mingzhu ^a   Fan, Lijun ^a   Zhang, Haiyu ^a   Zhao, Falin ^b   Zhang, Wang ^a   Ke, Chaofu ^a   Zhang, Guangming ^a   Hou, Yan ^a   Zhou, Xiaohua ^c   Lou, Ge ^a   Li, Kang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HANGZHOU NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Benign ovarian tumor; Epithelial ovarian cancer; Metabolomics; Plasma; UPLC MS

Indexed keywords

CA 125 ANTIGEN; PIPERIDONE DERIVATIVE; TRYPTOPHAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MASS SPECTROMETRY; METABOLOMICS; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADOLESCENT; ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MASS SPECTROMETRY; METABOLOME; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862814679     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.026     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician 1998, 57:2471-2476. 2479-2480.
3. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408.
4. Sjovall K., Nilsson B., Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002, 85:175-178.
5. Jacobs I.J., Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3:355-366.
6. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature 2008, 455:1054-1056.
7. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009, 15:431-440.
8. Claudino W.M., Quattrone A., Biganzoli L., Pestrin M., Bertini I., Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007, 25:2840-2846.
9. Qiu Y., Cai G., Su M., et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 2009, 8:4844-4850.
10. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clin Chim Acta 2009, 401:8-13.
11. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
12. 1H-NMR-based metabonomics. Int J Cancer 2005, 113:782-788.
13. Garcia E., Andrews C., Hua J., et al. Diagnosis of early stage ovarian cancer by (1)H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res 2011, 10:1765-1771.
14. Chen J., Zhang X., Cao R., et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res 2011, 10:2625-2632.
15. Woo H.M., Kim K.M., Choi M.H., et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009, 400:63-69.
16. Guan W., Zhou M., Hampton C.Y., et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics 2009, 10:259.
17. Bruce S.J., Tavazzi I., Parisod V., Rezzi S., Kochhar S., Guy P.A. Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. Anal Chem 2009, 81:3285-3296.
18. Dunn W.B., Broadhurst D., Begley P., et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6:1060-1083.
19. Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 2006, 78:779-787.
20. Smith C.A. LC/ MS preprocessing and analysis with xcms. Memory 2005, 1-13.
21. Tautenhahn R., Böttcher C., Neumann S. Annotation of LC/ESI-MS mass signals bioinformatics research and development 2007, 371-380. Springer Berlin, Heidelberg. S. Hochreiter, R. Wagner (Eds.).
22. Kuhl C., Tautenhahn R., Neumann S. LC-MS peak annotation and identification with CAMERA October 2010, 1-14.
23. Katajamaa M., Oresic M. Data processing for mass spectrometry-based metabolomics. J Chromatogr A 2007, 1158:318-328.
24. van den Berg R.A., Hoefsloot H.C., Westerhuis J.A., Smilde A.K., van der Werf M.J. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006, 7:142.
25. Sysi-Aho M., Katajamaa M., Yetukuri L., Oresic M. Normalization method for metabolomics data using optimal selection of multiple internal standards. BMC Bioinformatics 2007, 8:93.
26. Boulesteix A.L., Strimmer K. Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform 2007, 8:32-44.
27. Kruskal W., Wallis A. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952, 47:583-621.
28. Diz A.P., Carvajal-Rodriguez A., Skibinski D.O. Multiple hypothesis testing in proteomics: a strategy for experimental work. Mol Cell Proteomics 2011, 10. M110 004374.
29. Breiman L. RANDOM FORESTS. Mach learn 2001, 45:5-32.
30. Robin X., Turck N., Hainard A., et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011, 12:77.
31. Zou K.H., O'Malley A.J., Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007, 115:654-657.
32. R Development Core Team A language and environment for statistical computing.: R Foundation for Statistical Computing, Vienna, Austria 2010.
33. Kind T., Fiehn O. Advances in structure elucidation of small molecules using mass spectrometry. Bioanal Rev 2010, 2:23-60.
34. Wishart D.S., Knox C., Guo A.C., et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009, 37:D603-D610.
35. Smith C.A., O'Maille G., Want E.J., et al. METLIN: a metabolite mass spectral database. Ther Drug Monit 2005, 27:747-751.
36. Teneriello M.G., Park R.C. Early detection of ovarian cancer. CA Cancer J Clin 1995, 45:71-87.
37. Wiklund S., Nilsson D., Eriksson L., Sjöström M., Wold S., Faber K. A randomization test for PLS component selection. J Chemometr 2007, 21:427-439.
38. Schroecksnadel K., Winkler C., Fuith L.C., Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005, 223:323-329.
39. Sperner-Unterweger B., Neurauter G., Klieber M., et al. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology 2011, 216:296-301.
40. Huang A., Fuchs D., Widner B., Glover C., Henderson D.C., Allen-Mersh T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002, 86:1691-1696.
41. Lyon D.E., Walter J.M., Starkweather A.R., Schubert C.M., McCain N.L. Tryptophan degradation in women with breast cancer: a pilot study. BMC Res Notes 2011, 4:156.
42. Bryan G.T. The role of urinary tryptophan metabolites in the etiology of bladder cancer. Am J Clin Nutr 1971, 24:841-847.
43. Sutphen R., Xu Y., Wilbanks G.D., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:1185-1191.
44. Murph M., Tanaka T., Pang J., et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 2007, 433:1-25.
45. Iorio E., Mezzanzanica D., Alberti P., et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005, 65:9369-9376.
46. Westerhuis J., Hoefsloot H., Smit S. Assessment of PLSDA cross validation. Metabolomics 2008, 4:81-89.